Recombinant thymus pentapeptide structural analogs, its production and use
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- 广州达信生物技术有限公司
- Publication Date
- 2007-06-20
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention relates to the technical field of genetic engineering, in particular to a recombinant thymosin analogue and a preparation method thereof, and the application of the recombinant thymosin analogue in medicine for treating immune-related diseases. Background technique
[0002] U.S. Patents (U.S.Pat.Nos.4,190,646 and U.S.PaT.Nos.4,261,886) disclose artificially synthesized pentapeptides that have the same activity as human natural thymosin II (composed of 74 amino acids), and the sequence is H-ARG-LYS -ASP-VAL-TYR-OH, known as thymopentin (thymopentin or thymopoietin, TP); US patents (U.S. Pat. Nos. 4,002,740 and 4,077,949) reveal that thymopentin can selectively activate T cell differentiation, 1978 M.E. Weksler and others published an article in "Japanese Applied Medicine", claiming that thymopentin has a significant immune regulation function and has great medical application value.
[0003] Since then, a number of patents in the United S...